IL208836A0 - Long-acting y2 and/or y4 receptor agonists - Google Patents

Long-acting y2 and/or y4 receptor agonists

Info

Publication number
IL208836A0
IL208836A0 IL208836A IL20883610A IL208836A0 IL 208836 A0 IL208836 A0 IL 208836A0 IL 208836 A IL208836 A IL 208836A IL 20883610 A IL20883610 A IL 20883610A IL 208836 A0 IL208836 A0 IL 208836A0
Authority
IL
Israel
Prior art keywords
acting
long
receptor agonists
agonists
receptor
Prior art date
Application number
IL208836A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL208836A0 publication Critical patent/IL208836A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL208836A 2008-05-16 2010-10-20 Long-acting y2 and/or y4 receptor agonists IL208836A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08156360 2008-05-16
EP09154461 2009-03-05
PCT/EP2009/055989 WO2009138511A1 (en) 2008-05-16 2009-05-18 Long-acting y2 and/or y4 receptor agonists

Publications (1)

Publication Number Publication Date
IL208836A0 true IL208836A0 (en) 2011-01-31

Family

ID=40934036

Family Applications (1)

Application Number Title Priority Date Filing Date
IL208836A IL208836A0 (en) 2008-05-16 2010-10-20 Long-acting y2 and/or y4 receptor agonists

Country Status (12)

Country Link
US (1) US20110275559A1 (https=)
EP (1) EP2279204A1 (https=)
JP (1) JP2011520847A (https=)
KR (1) KR20110017874A (https=)
CN (1) CN102027007A (https=)
AU (1) AU2009248041B2 (https=)
BR (1) BRPI0912615A2 (https=)
CA (1) CA2723855A1 (https=)
IL (1) IL208836A0 (https=)
MX (1) MX2010011845A (https=)
RU (1) RU2504550C2 (https=)
WO (1) WO2009138511A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
EP2477643A1 (en) * 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011058165A1 (en) * 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
EP2600887A4 (en) 2010-07-09 2014-01-22 Amylin Pharmaceuticals Llc MICROCRYSTALLINE Y RECEPTOR AGONISTS
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
JP6672140B2 (ja) 2013-05-02 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１化合物の経口投薬
EP2842965A1 (en) 2013-09-03 2015-03-04 Gubra ApS Neuromedin U analogs comprising serum albumin binding amino acid residue
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
WO2015073878A1 (en) * 2013-11-15 2015-05-21 Ur Diet, Llc Real-time satiety biofeedback
MX369818B (es) 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
DK3068421T3 (da) * 2013-11-15 2019-06-24 Novo Nordisk As Selektive pyy-forbindelser og anvendelser deraf
US20240100450A9 (en) * 2014-01-17 2024-03-28 Repligen Corporation Sterilizing chromatography columns
US10610807B2 (en) 2014-01-17 2020-04-07 Repligen Corporation Sterilizing chromatography columns
CN114805527A (zh) * 2014-05-21 2022-07-29 哈佛大学的校长及成员们 Ras抑制肽和其用途
MA43205A (fr) 2015-06-12 2018-09-19 Novo Nordisk As Composés pyy sélectifs et leurs utilisations
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
TWI749381B (zh) * 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
GB201908426D0 (en) * 2019-06-12 2019-07-24 Imp College Innovations Ltd Appetite suppressing compounds
AU2021257477A1 (en) * 2020-04-17 2022-12-08 I2O Therapeutics, Inc. Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use
CA3215858A1 (en) 2021-04-27 2022-11-03 Zhenhuan ZHENG Combination of bitter receptor agonist and gut-signaling compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273713B2 (en) * 2000-12-14 2012-09-25 Amylin Pharmaceuticals, Llc Methods of treating obesity using PYY[3-36]
KR101241862B1 (ko) * 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
WO2005077094A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
CA2560174A1 (en) * 2004-03-17 2005-09-29 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
MXPA06015049A (es) * 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
AU2006271792A1 (en) * 2005-07-18 2007-01-25 Novo Nordisk A/S Peptides for use in the treatment of obesity

Also Published As

Publication number Publication date
MX2010011845A (es) 2010-11-22
BRPI0912615A2 (pt) 2016-01-26
CA2723855A1 (en) 2009-11-19
EP2279204A1 (en) 2011-02-02
RU2010149474A (ru) 2012-06-27
RU2504550C2 (ru) 2014-01-20
WO2009138511A1 (en) 2009-11-19
JP2011520847A (ja) 2011-07-21
CN102027007A (zh) 2011-04-20
KR20110017874A (ko) 2011-02-22
AU2009248041B2 (en) 2013-10-03
AU2009248041A1 (en) 2009-11-19
US20110275559A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
IL208836A0 (en) Long-acting y2 and/or y4 receptor agonists
IL213569A0 (en) Gpr120 receptor agonists and uses thereof
EP2173174A4 (en) FARNESOID X RECEPTOR AGONISTS
EP2170072A4 (en) Farnesoid X RECEPTOR AGONISTS
IL208919A0 (en) Gpr119 receptor agonists
EP2306994A4 (en) S1P1 RECEPTOR AGONISTS AND USES
IL210506A0 (en) Complement antagonists and uses thereof
ZA201009009B (en) Aryl gpr119 agonists and uses thereof
PT2318366T (pt) Agentes de ligação a psma e suas utilizações
IL211742A0 (en) Frizzled-binding agents and uses thereof
IL210773A0 (en) Neuropeptide-2 receptor (y-2r) agonists and uses thereof
EP2318618A4 (en) construction support
IL212468A0 (en) Melanocortin receptor agonists
IL209492A0 (en) Personal load carrying release
GB0822154D0 (en) Recepatacle and support
IL212364A0 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
EP2262371A4 (en) LPA RECEPTOR AGONISTS AND ANTAGONISTS
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
EP2247601A4 (en) THIAZOPYRIMIDINONE AND APPLICATIONS THEREOF
GB2458890B (en) Support anchor
GB0814548D0 (en) Tile and tile holding device
AU4585P (en) WES05 Westringia fruticosa
GB0807710D0 (en) Receptor and modulators thereof
GB0818393D0 (en) Dispenser and support member
AU320444S (en) Tilting bollard